CATX vs LNTH
CATX: A clinical-stage radiopharmaceutical company pioneering 212Pb-based alpha-emitter therapies and theranostics for precision oncology. LNTH: Lantheus is a specialist in diagnostic imaging agents and radiopharmaceuticals that help clinicians visualize cardiovascular conditions and oncological disease states.
Side-by-side fundamentals
| Metric | CATX | LNTH | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.71 | $100.12 | |
| Market cap | $309M | $6.5B | |
| P/E as of 2026-10-08 | n/a | 24.22 | |
| Net margin FY2025, SEC XBRL | n/a | +15.2% | |
| Gross margin FY2025, SEC XBRL | n/a | +61.1% | |
| Operating margin FY2025, SEC XBRL | n/a | +20.2% | |
| ROE FY2025, SEC XBRL | -49.8% | +21.4% | LNTH higher |
| ROA FY2025, SEC XBRL | -38.6% | +10.5% | LNTH higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.44 | CATX lower |
| Revenue growth (YoY) as of 2026-09-03 | -58.0% | +2.4% | LNTH higher |
| Revenue CAGR (3y) SEC XBRL | +11.4% | +18.1% | LNTH higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.56 | 0.38 | |
| 1-year return as of 2026-10-08 close | -29.8% | +87.0% | LNTH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.